**Name of Journal: *World Journal of Methodology***

**ESPS Manuscript NO: 21044**

**Manuscript Type: Minireviews**

**Monitoring anticoagulant therapy with new oral agents**

Ramos-Esquivel A. Anticoagulation monitoring

**Allan Ramos-Esquivel**

**Allan Ramos-Esquivel,** Department of Pharmacology, School of Medicine,University of Costa Rica, San José 11501-2060, Costa Rica

**Author contributions:** The author solely contributed to this paper.

**Conflict-of-interest statement:** There are not any conflicts of interest to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Allan Ramos-Esquivel,** **MD, MSc,** Department of Pharmacology, School of Medicine, University of Costa Rica,Sede Rodrigo Facio, San Pedro Calle 27, San José 11501-2060, Costa Rica. allanramoscr@gmail.com

**Telephone:** +506-8844-8187

**Fax:** +506-2237-3930

**Received:** June 28, 2015

**Peer-review started:** July 5, 2015

**First decision:** July 28, 2015

**Revised:** September 22, 2015

**Accepted:** October 12, 2015

**Article in press:**

**Published online:**

**Abstract**

Thromboembolic disease is a major leading cause of mortality and morbidity in industrialized countries. Currently, the management of these patients is challenging due to the availability of new drugs with proven efficacy and security compared to traditional oral vitamin K antagonists. These compounds are characterized by a predictable pharmacokinetic profile for which blood monitoring is not routinely needed. Nevertheless, some data have suggested inter-patient variability in the anticoagulant effect of these drugs, raising concerns about their effectiveness and safety. Although mass-spectrometry is the gold standard to determine drug plasma concentrations, this method is not widely available in every-day practice and some coagulation assays are commonly used to determine the anticoagulant effect of these drugs. The present review aims to summarize the current knowledge regarding the clinical question of how and when to monitor patients with new anticoagulant oral agents.

**Key words:** Anticoagulant agents; Apixaban; Dabigatran; Drug monitoring; Rivaroxaban

© **The Author(s) 2015**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** New oral anticoagulants are replacing oral vitamin K antagonists for some practical advantages, like unnecessary monitoring and a better pharmacokinetic profile. Nevertheless, in some circumstances, their anticoagulant activity must be monitored in order to prevent adverse outcomes. In this minireview a list of the available laboratory test are reviewed to better understand the pros and cons of each analysis.

Ramos-Esquivel A. Monitoring anticoagulant therapy with new oral agents. *World J Methodol* 2015; In press

**INTRODUCTION**

The management of thromboembolic disease has always been challenging since current treatments involve an inherent risk of bleeding that must be counterbalanced by the anticoagulant effect of each drug.

The use of vitamin K antagonists, such as warfarin, implies the monitoring of their anticoagulant effect through frequent blood tests and the education of patients about potential drug and food interactions, making their use puzzling and difficult for many clinicians. In contrast, new agents have shown some advantages over vitamin K antagonists, since no dose adjustment and monitoring is routinely needed, as a consequence of a “more favorable pharmacokinetic profile”. In addition, these new drugs, usually mentioned as new oral anticoagulants (NOACs), have demonstrated clinical efficacy and a better security profile than warfarin in various clinical trials, making attractive their use in clinical practice[1-3].

However, recent data have emerged regarding a potential role for monitoring the anticoagulant effect of these drugs particularly in patients with specific circumstances and comorbidities in order to reduce side effects and improve efficacy[4-7].

Some recommendations to measure the anticoagulant effect of NOACs include the following scenarios[8,9]: (1) Bleeding or recurrence of thrombosis; (2) Before surgery or any invasive procedure when the patient has taken the drug in the previous 24 h or longer if creatinine clearance is less than 50 mL/min; (3) Identification of supra or subtherapeutic levels in patients taking other drugs with potential interactions, or in patients with extreme body weight; (4) Patients with renal failure or prompt to it; (5) Reversal of anticoagulation; (6) Suspicion of drug overdose; (7) Patients with genetic mutations (*e.g.*, rs2244613 minor allele carriers for dabigatran etexilate); and (8) Assessment of compliance.

Although it is desirable to explore the anticoagulant effect of these drugs in the aforementioned circumstances, some cons have also emerged and detractors of routine monitoring include the following reasons in their arguments[10]: (1) Lack of measures in clinical trials; (2) Wide therapeutic window of some of these agents; (3) There is no a standardized clinical method to detect the anticoagulant effect or it is not yet available; and (4) The interpretation and dose adjustments have not been established.

**PHARMACOLOGY OF NOACS**

NOACs are categorized according to their site of action; apixaban and rivaroxaban act by inhibiting factor Xa, thereby decreasing the conversion of prothrombin to thrombin. On the other hand, dabigatran acts by directly inhibiting thrombin. Table 1 summarizes some pharmacokinetics features of clinical utility for these agents. Of particular interest is the renal clearance of these drugs that modifies or prohibits their use in case of severe kidney failure.

Although it is thought that there are fewer drug interactions for NOACs than for warfarin, clinical data suggest moderate to severe drug-drug interactions when dabigatran is used in combination with verapamil, amiodarone, and dronedarone[13,14].

Similarly, some other drugs commonly known as CYP inhibitors such as ketoconazole, itraconazole, macrolides, human immunodeficiency virus protease inhibitors can increase the serum NOACs concentration. On the other hand, some CYP inductors, such as phenytoin, phenobarbital, rifampicin and carbamazepine can decrease the anticoagulant effect of NOACs and thus are not generally recommended in these patients.

**DETERMINING ANTICOAGULATION LEVELS WITH THE NOACS**

The gold standard to measure plasma drug concentrations is mass-spectrometry. Nevertheless, the availability and laboratory expertise for doing this specialized technique is not fulfilled in the majority of clinical centers. For this reason, some other test must be carried out in order to determine the anticoagulant effect of NOACs. Table 2 resumes the advantages and drawbacks of available coagulation tests that have been used to determine the anticoagulat effect of NOACs in clinical settings.

***Dabigatran***

**Activated partial thromboplastin time and thrombin time:** These are very sensitive assays that do not accurately reflect plasma dabigatran concentrations. Although they are widely available, they are affected by a lot of variables such as inappropriate collection, improper handling and storage. Besides neither are strong predictors of bleeding, and patients may present any kind of hemorrhage even when the activated partial thromboplastin time and/or thrombin time are within normal range[15].

**Diluted thrombin time:** Since assays to evaluate thrombin activity are very sensitive to determine the anticoagulant effect of dabigatran, the use of diluted plasma in conjunction with the Hemoclot thrombin inhibitor permits to easily measure dabigatran anticoagulant activity[16].

**Ecarin clotting time and ecarin chromogenic assay:** These assays are not widely available and calibration is required to perform these tests. They use a metalloprotease called ecarin and are very specific for anti thrombin inhibitors due to the fact that prothrombin is a substrate for these analyses[17].

***Rivaroxaban***

**Prothrombin time:** The Subcommittee of Control of Anticoagulation of the Scientific and Standardization Committee recommends that this assay can determine the relative intensity of anticoagulation in patients taking rivaroxaban but it is not useful to extrapolate plasma concentrations. Besides, it has different sensitivities according to the type of the employed reagent with high variability among laboratories[8,18].

**Dilute Russell’s viper venom time:** This is a useful test to determine the anticoagulant effect of Xa and thrombin inhibitors since Russell’s viper venom contains a potent activator of factor X and II. Nevertheless, validation and calibrations are technical issues that must be explored in future trials to determine a valid cut off and their sensitivity is low[19].

**Chromogenic anti-Xa assay:** Plasma concentrations of rivaroxaban and anti-Xa levels correlate fairly well and it is the preferred method to estimate plasma concentrations. This method is less affected by sample handling or clotting factors in patients. However, a major limitation is the standardization and the availability of laboratories with specific calibrators and controls[20].

***Apixaban***

**Dilute Russell’s viper venom time:** As pointed before, this test is very useful and sensitive to determine the anticoagulant effect of apixaban, but with a low specificity.

**Chromogenic anti-Xa assay:** It is the most sensitive assay to determine the inhibition of factor Xa by apixaban and it is recommended to estimate plasma concentrations of this drug. Nevertheless, this test is not widely available and it is time consuming[21].

**SPECIAL CONSIDERATIONS**

It is important to point out that any of these analyses have been tested in special populations such as elderly patients and children, as well as pregnant women and individuals with multiple morbidities[22,23]. Besides, some methodological issues regarding sample collection must be accomplished to avoid misinterpretations and biases. For example, plasma concentrations of the NOACs can vary among 10 to 20 times between peak and trough concentrations. Therefore, the assessment of the anticoagulant activity of each drug should be obtained immediately prior to the next scheduled dose[22]. Furthermore there are few reports regarding a correlation between any of these tests and the efficacy and security of any NOAC and the clinical significance of these analyses must be interpreted cautiously.

**CONCLUSIONS**

Despite of the potentials scenarios in which the role of monitoring the anticoagulant effect of NOAC can be clinically valid, it must be point out that there is no trial which has compared results of these drugs with or without coagulation monitoring and there are no guidelines to determine the steps to follow in order to improve the quality of the anticoagulation therapy. Nevertheless, with the broad use of NOACs in clinical practice we must keep in mind the inter-patient variability of these drugs that can result in loss of efficacy and security.

**REFERENCES**

1 **Patel MR**, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011; **365**: 883-891 [PMID: 21830957 DOI: 10.1056/NEJMoa1009638]

2 **Granger CB**, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011; **365**: 981-992 [PMID: 21870978 DOI: 10.1056/NEJMoa1107039]

3 **Connolly SJ**, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009; **361**: 1139-1151 [PMID: 19717844 DOI: 10.1056/NEJMoa0905561]

4 **Freyburger G**, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. *Thromb Res* 2011; **127**: 457-465 [PMID: 21277622 DOI: 10.1016/j.thromres.2011.01.001]

5 **Paré G**, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. *Circulation* 2013; **127**: 1404-1412 [PMID: 23467860 DOI: 10.1161/CIRCULATIONAHA.112.001233]

6 **Reilly PA**, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; [RE-LY Investigators](http://www.ncbi.nlm.nih.gov/pubmed/?term=RE-LY%20Investigators%5BCorporate%20Author%5D). The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *J Am Coll Cardiol* 2014; **63**: 321-328 [PMID: 24076487 DOI: 10.1016/j.jacc.2013.07.104]

7 **Southworth MR**, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. *N Engl J Med* 2013; **368**: 1272-1274 [PMID: 23484796 DOI: 10.1056/NEJMp1302834]

8 [**Baglin T**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Baglin%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23347120), [Hillarp A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hillarp%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23347120), [Tripodi A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Tripodi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23347120), [Elalamy I](http://www.ncbi.nlm.nih.gov/pubmed/?term=Elalamy%20I%5BAuthor%5D&cauthor=true&cauthor_uid=23347120), [Buller H](http://www.ncbi.nlm.nih.gov/pubmed/?term=Buller%20H%5BAuthor%5D&cauthor=true&cauthor_uid=23347120), [Ageno W](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ageno%20W%5BAuthor%5D&cauthor=true&cauthor_uid=23347120). Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost* 2013 Jan 24; Epub ahead of print [PMID: 23347120 DOI: 10.1111/jth.12149]

9 **Douxfils J**, Mani H, Minet V, Devalet B, Chatelain B, Dogné JM, Mullier F. Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. *Biomed Res Int* 2015; **2015**: 345138 [PMID: 26090400 DOI: 10.1155/2015/345138]

10 **Samama MM**, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. *Thromb Res* 2012; **130** Suppl 1: S88-S89 [PMID: 23026675 DOI: 10.1016/j.thromres.2012.08.286]

11 **Eriksson BI**, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. *Clin Pharmacokinet* 2009; **48**: 1-22 [PMID: 19071881 DOI: 10.2165/0003088-200948010-00001]

12 **Poulsen BK**, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. *Drugs* 2012; **72**: 1739-1753 [PMID: 22931521 DOI: 10.2165/11635730-000000000-00000]

13 **Liesenfeld KH**, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. *J Thromb Haemost* 2011; **9**: 2168-2175 [PMID: 21972820 DOI: 10.1111/j.1538-7836.2011.04498.x]

14 **Mueck W**, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. *Br J Clin Pharmacol* 2013; **76**: 455-466 [PMID: 23305158 DOI: 10.1111/bcp.12075]

15 **Stangier J**, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. *Br J Clin Pharmacol* 2007; **64**: 292-303 [PMID: 17506785 DOI: 10.1111/j.1365-2125.2007.02899.x]

16 **Hapgood G**, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. *Thromb Haemost* 2013; **110**: 308-315 [PMID: 23783268 DOI: 10.1160/TH13-04-0301]

17 **Antovic JP**, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg EM, Onelöv L, Rönquist-Nii Y, Pohanka A, Beck O, Hjemdahl P, Malmström RE. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. *Eur J Clin Pharmacol* 2013; **69**: 1875-1881 [PMID: 23784008 DOI: 10.1007/s00228-013-1550-4]

18 **van Veen JJ**, Smith J, Kitchen S, Makris M. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. *Br J Haematol* 2013; **160**: 859-861 [PMID: 23278675 DOI: 10.1111/bjh.12173]

19 **Exner T**, Ellwood L, Rubie J, Barancewicz A. Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study. *Thromb Haemost* 2013; **109**: 762-765 [PMID: 23364321 DOI: 10.1160/TH12-11-0842]

20 **Douxfils J**, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné JM, Mullier F. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. *Thromb Haemost* 2013; **110**: 723-731 [PMID: 23846172 DOI: 10.1160/TH13-04-0274]

21 **Frost C**, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, Lacreta F. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. *Br J Clin Pharmacol* 2013; **76**: 776-786 [PMID: 23451769 DOI: 10.1111/bcp.12106]

22 **Garcia D**, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. *J Thromb Haemost* 2013; **11**: 245-252 [PMID: 23216682 DOI: 10.1111/jth.12096]

23 **Favaloro EJ**, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. *Biochem Med* (Zagreb) 2012; **22**: 329-341 [PMID: 23092064 DOI: 10.11613/BM.2012.035]

**P- Reviewer:** Fukuda S, Redondo PC **S- Editor:** Gong XM

 **L- Editor:** **E- Editor:**

**Table 1 Pharmacokinetic features of new oral anticoagulants[11,12]**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Apixaban** | **Rivaroxaban** | **Dabigatran** |
| Posology | Twice daily | Once daily | Twice daily |
| Oral bioavailability  | 45% | > 80% | 6% |
| Half life | 12 h | 7-11 h | 12-17 h |
| Excretion | 25% renal | 66% renal (active and inactive) | 80% renal |

**Table 2 Available coagulation tests to determine the anticoagulant effect of oral anticoagulants**

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug** | **Coagulation test** | **Pros** | **Cons** |
| Dabigatran | aPTT | Highly available | Do not reflect the intensity of coagulationLow specificity |
| TT | Highly available | It only determines the effect of dabigatran but lacks specificity |
| dTT | Very accurate and precise to estimates plasma concentrations of dabigatran | Requires specific calibrators and controls in specialized laboratories with trained personalLow specificity |
| ECT |  | Requires specific calibrators and controls in specialized laboratories with trained personalLimited standardization and validation requiredLow specificityInterlot variability reported |
| ECA | Very accurate and precise to estimates plasma concentrations of dabigatran | Requires specific calibrators and controls in specialized laboratories with trained personalLow specificity |
| DRVV-T |  | Requires specific calibrators and controls in specialized laboratories with trained personalLow specificity |
| Rivaroxaban | PT | Highly available | Do not reflect the intensity of coagulationLow specificity |
| Rivaroxaban and Apixaban | Chromogenic anti-Xa assays | Very accurate and precise to estimates plasma concentrations of dabigatran | Requires specific calibrators and controls in specialized laboratories with trained personal |
| DRVV-T |  | Requires specific calibrators and controls in specialized laboratories with trained personalLow specificity |

Any of these tests have been associated with clinical endpoints and data regarding their use in special populations are scarce. aPTT: Activated partial thromboplastin time; DRVV-T: Dilute Russell’s viper venom time; dTT: Dilute thrombin time; ECA: Ecarin chromogenic assay; ECT: Ecarin clotting time; PT: Prothrombin time; TT: Thrombin time.